Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Multiple Cancer Types

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care. The study will last up to approximately 2 years.
Colon, Gastrointestinal, Lung, Miscellaneous, Non Small Cell, Phase I, Rectal
I
Iams, Wade
NCT04956640
VICCTHOP2155

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: